GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Inventories, Raw Materials & Components

BJDX (Bluejay Diagnostics) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Inventories, Raw Materials & Components?

Bluejay Diagnostics's inventories, raw materials & components for the quarter that ended in Dec. 2024 was $0.00 Mil.


Bluejay Diagnostics Inventories, Raw Materials & Components Historical Data

The historical data trend for Bluejay Diagnostics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics Inventories, Raw Materials & Components Chart

Bluejay Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

Bluejay Diagnostics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bluejay Diagnostics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Bluejay Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
Executives
Svetlana Dey director, 10 percent owner 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey director, 10 percent owner, officer: Chief Technology Officer 360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally officer: CFO 66 MELANIE LANE, SYOSSET NY 11791
Jason Cook officer: Chief Technology Officer 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher officer: Chief Financial Officer 67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth director, 10 percent owner 4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder officer: Chief Financial Officer 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani director C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman director 109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase director 39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089